Tricyclic spiro compound
US-10077247-B2 · Sep 18, 2018 · US
Method for treating brain tumors
US10617667B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10617667-B2 |
| Application number | US-201816176361-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 31, 2018 |
| Priority date | Nov 1, 2017 |
| Publication date | Apr 14, 2020 |
| Grant date | Apr 14, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are a method for treating brain tumors, as well as a medicament for treating brain tumors. Provided is a medicament for treating brain tumors, the medicament containing a combination of 4-[4-cyano-2-({[(2′R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid or a pharmaceutically acceptable salt thereof, and an anti-PD-1 antibody. The combination exhibits an excellent effect for treating brain tumors, and is thus useful to treat brain tumors.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a glioma, the method comprising simultaneously or separately administering an effective amount of 4-[4-cyano-2-({[(2′R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid or a pharmaceutically acceptable salt thereof, and an effective amount of an anti-PD-1 antibody to a subject in need thereof. 2. The method according to claim 1 , wherein the anti-PD-1 antibody is administered to the subject to whom the 4-[4-cyano-2-({[(2′R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid or a pharmaceutically acceptable salt thereof was previously administered. 3. The method according to claim 1 , wherein the 4-[4-cyano-2-({[(2′R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid or a pharmaceutically acceptable salt thereof is administered to the subject to whom the anti-PD-1 antibody was previously administered. 4. A method for treating a glioma, the method comprising administering an effective amount of an anti-PD-1 antibody to a subject in need thereof, the method further comprising administering an effective amount of 4-[4-cyano-2-({[(2′R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid or a pharmaceutically acceptable salt thereof. 5. A method for treating a glioma, the method comprising administering an effective amount of 4-[4-cyano-2-({[(2′R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid or a pharmaceutically acceptable salt thereof to a subject in need thereof, the method further comprising administering an effective amount of an anti-PD-1 antibody. 6. The method according to claim 1 , wherein the anti-PD-1 antibody is intravenously or subcutaneously administered. 7. The method according to claim 1 , wherein the anti-PD-1 antibody is nivolumab. 8. The method according to claim 2 , wherein the anti-PD-1 antibody is intravenously or subcutaneously administered. 9. The method according to claim 2 , wherein the anti-PD-1 antibody is nivolumab. 10. The method according to claim 3 , wherein the anti-PD-1 antibody is intravenously or subcutaneously administered. 11. The method according to claim 3 , wherein the anti-PD-1 antibody is nivolumab. 12. The method according to claim 4 , wherein the anti-PD-1 antibody is intravenously or subcutaneously administered. 13. The method according to claim 4 , wherein the anti-PD-1 antibody is nivolumab. 14. The method according to claim 5 , wherein the anti-PD-1 antibody is intravenously or subcutaneously administered. 15. The method according to claim 5 , wherein the anti-PD-1 antibody is nivolumab.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title
against CD28 or CD152 · CPC title
- A61K31/353Primary
3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title
comprising antibodies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10617667B2 cover?
- Disclosed are a method for treating brain tumors, as well as a medicament for treating brain tumors. Provided is a medicament for treating brain tumors, the medicament containing a combination of 4-[4-cyano-2-({[(2′R,4S)-6-(isopropylcarbamoyl)-2,3-dihydrospiro[chromene-4,1′-cyclopropan]-2′-yl]carbonyl}amino)phenyl]butanoic acid or a pharmaceutically acceptable salt thereof, and an anti-PD-1 ant…
- Who is the assignee on this patent?
- Ono Pharmaceutical Co, Univ California
- What technology area does this patent fall under?
- Primary CPC classification A61K31/353. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).